AN2 Therapeutics Starts First Human Trial of Oral AN2-502998

AN2 Therapeutics, a company working on new drug tech, shared that it has finished the first round of doses in a test of its new drug, AN2-502998. This test looks at how safe and effective the drug is in healthy people. They plan to finish this test phase by the end of 2025.

AN2-502998 could be a new cure for chronic Chagas disease, an illness from a bug that impacts about 6 to 7 million people all over the world. Even though lots of people have it, many do not show signs and need better treatment.

Tests on animals showed the drug could really cure this disease, which makes the team hopeful it will work in people too.

Also Read: New Antibiotic Regimen Eases Staph Infection Treatment

"This is a big step for us and for those with chronic Chagas disease," said Eric Easom, Co-Founder, Chairman, President, and CEO of AN2 Therapeutics, who helps lead AN2 Therapeutics. "Our drug could be the first cure taken by mouth for this disease that many forget about. We want to change how patients are treated."

The company also talked about working with the Drugs for Neglected Diseases initiative (DNDI) to speed up work on the drug. They are getting ready for the next-step trial and think they might have some early results soon.

AN2 keeps working hard to bring new treatments for ignored diseases by developing new small drugs.